| Schedule of Segment Reporting Information, by Segment |
The following tables summarize, for the periods indicated, operating results by reportable segment: Cost of goods sold is directly related to product sales only. Revenues derived from co-promote revenue had no cost of goods sold. | | | Dermatology | | Pharmaceutical
and
Biotechnology | | | | | | | | | ($ in thousands) | | Products | | Product | | | | | | | | | Three Months Ended March 31, 2018 | | Sales | | Development | | National | | Consolidated | | | Net Revenue | | $ | 5,509 | | $ | 394 | | $ | 49,522 | | $ | 55,425 | | | Direct cost of goods | | | (1,472) | | | - | | | - | | | (1,472) | | | Sales and marketing costs | | | (2,764) | | | - | | | - | | | (2,764) | | | Research and development | | | - | | | (25,055) | | | - | | | (25,055) | | | General and administrative | | | (397) | | | (10,387) | | | - | | | (10,784) | | | National Expenses | | | - | | | - | | | (50,836) | | | (50,836) | | | Segment income (loss) from operations | | $ | 876 | | $ | (35,048) | | $ | (1,314) | | $ | (35,486) | | | Segment assets | | $ | 11,163 | | $ | 189,560 | | $ | 64,352 | | $ | 265,075 | | | | | Dermatology | | Pharmaceutical
and
Biotechnology | | | | | | | | | ($ in thousands) | | Products | | Product | | | | | | | | | Three Months Ended March 31, 2017 | | Sales | | Development | | National | | Consolidated | | | Net Revenue | | $ | 2,085 | | $ | 693 | | $ | 41,904 | | $ | 44,682 | | | Direct cost of goods | | | (469) | | | - | | | - | | | (469) | | | Sales and marketing costs | | | (2,267) | | | - | | | - | | | (2,267) | | | Research and development | | | - | | | (8,404) | | | - | | | (8,404) | | | General and administrative | | | (319) | | | (7,666) | | | - | | | (7,985) | | | National Expenses | | | - | | | - | | | (43,134) | | | (43,134) | | | Segment loss from operations | | $ | (970) | | $ | (15,377) | | $ | (1,230) | | $ | (17,577) | | | Segment assets | | $ | 4,039 | | $ | 159,175 | | $ | 48,697 | | $ | 211,911 | |
|